🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. FLUOROURACIL , OXALIPLATIN , GEMCITABINE , FOLIC ACID

    Pari Pharma GmbH

    Pancreatic adenocarcinoma (PAC)

    phase 3 small molecule active

    1 trial

  2. FLUOROURACIL, BEVACIZUMAB, FOLINIC ACID, OXALIPLATIN, ivonescimab

    Summit Therapeutics

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  3. FLUOROURACIL, CAPECITABINE, Zimberelimab, OXALIPLATIN, FLUOROURACIL, CALCIUM FOLINATE, DOMVANALIMAB, NIVOLUMAB, FLUOROURACIL, CAPECITABINE

    Arcus Biosciences

    Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer

    phase 3 small molecule active

    1 trial

  4. FLUOROURACIL, CISPLATIN, CAPECITABINE, CISPLATIN, TRASTUZUMAB, Placebo for Pembrolizumab, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, TRASTUZUMAB

    Merck Sharp and Dohme

    Gastric or gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  5. FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE

    Verona Pharma Ireland Limited

    Gastric adenocarcinoma with peritoneal metastases

    phase 3 small molecule active

    1 trial

  6. FLUOROURACIL, Tecentriq 1 200 mg concentrate for solution for infusion, CALCIUM FOLINATE PENTAHYDRATE, OXALIPLATIN

    The George Institute

    stage III colon adenocarcinoma with deficient MMR

    phase 3 small molecule active

    1 trial

  7. FOSFOMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM

    Tour Hekla

    Benign Prostate Hyperplasia

    phase 3 small molecule active

    1 trial

  8. Febuxostat IR

    Takeda

    Gout

    phase 3 small molecule completed

    2 trials

  9. Femara 2.5 mg film-coated tablets, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Anastrozole 1mg film-coated tablets, Docetaxel Pfizer 10 mg/mL concentrate for solution for infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Exemestane 25 mg Film-coated Tablets, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Ningbo Cancer Hospital

    low-grade serous carcinoma of the ovary or peritoneum

    phase 3 small molecule active

    1 trial

  10. Fibrinogen (human) + thrombin (human) (TachoSil)

    Takeda

    Surgical Resection of Superficial Renal Tumour

    phase 3 other completed

    1 trial

  11. Ficerafusp alfa

    Bicara Therapeutics

    Metastatic Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  12. Film-Coated Tablet without Deucravacitinib, Film-Coated Tablet without JNJ-77242113, DEUCRAVACITINIB, JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  13. Film-Coated Tablet without JNJ-77242113, JNJ-77242113

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  14. Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)

    Hoffmann-La Roche

    Early Breast Cancer

    phase 3 small molecule completed

    1 trial

  15. GEMCITABINE, Mrtx1719 matching placebo, PACLITAXEL ALBUMIN-BOUND, MRTX1719

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  16. GEMCITABINE, PEGFILGRASTIM, PACLITAXEL ALBUMIN-BOUND, BL-B01D1, CAPECITABINE, CARBOPLATIN, PACLITAXEL, CAPECITABINE

    Bristol-Myers Squibb Australia Pty Ltd

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  17. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Seizure in Participants With Tuberous Sclerosis Complex

    phase 3 small molecule terminated

    1 trial

  18. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Tuberous Sclerosis Complex

    phase 3 small molecule completed

    2 trials

  19. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Merck Sharp and Dohme

    ​9vHPV vaccine is indicated in females ≥ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.​

    phase 3 small molecule active

    1 trial

  20. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Placebo formulation of Gardasil, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    The George Institute

    Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.

    phase 3 small molecule active

    1 trial

  21. Gazyvaro 1,000 mg concentrate for solution for infusion., Prograf 1 mg Hartkapseln, Prograf 0,5 mg Hartkapseln, Prograf 5 mg Hartkapseln

    Hoffmann-La Roche

    Primary Membranous Nephropathy (pMN)

    phase 3 small molecule active

    1 trial

  22. Gemcitabine Eugia 40 mg/ml solution à diluer pour perfusion, RILVEGOSTOMIG, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Hihg risk of cholangiocarcinoma intra hépatic resectable

    phase 3 small molecule active

    1 trial

  23. Grafalon 20 mg/ml concentrato per soluzione per infusione

    The George Institute

    To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.

    phase 3 small molecule active

    1 trial

  24. Gum chewing

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Recovery of Bowel Function, Due to Gum Chewing

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources